Inhibitors of EZH2
US9718838B2 · kind B2 · utility
8Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 22, 2016 |
| Grant date | Aug 1, 2017 |
| Priority date | — |
| Expiry date | Aug 22, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.